GlobeNewswire by notified

SPEE3D LAUNCHES EXPEDITIONARY MANUFACTURING UNIT (EMU) – THE COMPLETE MOBILE ADDITIVE MANUFACTURING SOLUTION AT AM VILLAGE

Share

EMU Enables Industries with Large Industrial Equipment, Including Defence, Mining, and Marine, to Quickly Print and Replace Large Metal Parts in the Field

Melbourne, Australia and Tournai, Belgium, May 14, 2024 (GLOBE NEWSWIRE) -- SPEE3D, a leading metal additive manufacturing company, announced the launch of its Expeditionary Manufacturing Unit (EMU), the complete on-site mobile additive manufacturing solution. EMU combines SPEE3D’s expeditionary metal 3D printer, XSPEE3D, with its SPEE3Dcell post-processing and testing unit in two 20-foot shipping containers, which together can produce cast-equivalent metal parts in record time close to the point of need.

Participating in the European Defence Agency’s AM Village 2024 Workshop in Tournai, Belgium, SPEE3D will demonstrate its deployable technology alongside the British Army to militaries from over 25 EU and NATO countries.

SPEE3D’s EMU enables the replacement of metal parts in hours instead of days or weeks, minimizing the cost of disruption and downtime. Unlike other additive manufacturing solutions, the EMU does not require dangerous and expensive lasers or inert gasses. Additionally, no extensive prior expertise with additive manufacturing technology is required.

"The launch of our Expeditionary Manufacturing Unit addresses the current state of the global supply chain, which is fragile and increasingly under pressure," said Byron Kennedy, CEO of SPEE3D. "Part of the issue for defence and other heavy industries is getting critical equipment up and running quickly to avoid costly production delays. EMU will enable the British Army and others to take control, giving them the ability to print and post-process parts very quickly from anywhere."

The system includes two 20-foot containers with twist locks, a ruggedized, mobile metal 3D printer that can produce high-density metal parts in a wide range of materials, and a fully-equipped post-processing shop – including a heat treatment furnace, CNC three-axis mill, tooling, and testing equipment. As a truly expeditionary product, EMU can be transported on a single platform (truck trailer/ship/plane).

“Through its continual programme of modernisation, the British Army embraces new innovative manufacturing solutions to keep it at the forefront of emerging technology and at a tactical advantage over its potential adversaries,” said a UK Army spokesperson. “Our collaboration with SPEE3D has produced the world’s first fully field deployable 3D cold metal printing capability, heralding a step change in deployable engineering capabilities for our forces deployed overseas.”

SPEE3D works extensively with defence around the world, including the Japanese, US, UK, and Australian Defence forces. Last fall, a team was in Poland training Ukrainian military personnel on the technology. In the future, SPEE3D will be working with the UAE Military of Defense.

About SPEE3D:

SPEE3D is a leading metal additive manufacturing technology company dedicated to the research, development, and delivery of metal 3D printers and integrated systems utilizing its patented Cold Spray Additive Manufacturing (CSAM) technology. As a result, SPEE3D’s product portfolio enables significantly faster production than traditional metal manufacturing for a wide range of metals, including copper, aluminum, stainless steel, and aluminum bronze. To learn more, visit www.spee3d.com.



Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.21.5.2024 02:25:00 CEST | Press release

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® REYKJAVIK, ICELAND & PARSIPPANY, NJ— Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. “We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey, Senior Vice President, U.S. Market Access at Teva. “Biosimilars create opportunities for cost savings across the healthcare system, and SIMLANDI’s launch now offers the first citrate-free, high-concentration biosimilar to be designated interchangeable to Hu

IDEX Biometrics – Number of shares in Tranche 1 vs Tranche 2 in the private placement on 15 May 202420.5.2024 23:52:54 CEST | Press release

Reference is made to the stock exchange announcement by IDEX Biometrics ASA (the “Company”) on 15 May 2024 regarding a successful private placement of shares. By inadvertence, the announcement contained a slight error in the allocation of private placement shares between Tranche 1, as issued by the Board pursuant to an authorization to issue shares granted by the extraordinary general meeting dated 21 December 2023, and Tranche 2, to be issued subject to approval by an extraordinary general meeting to be called and scheduled for on or about 12 June 2024. The correct number of Tranche 1 shares is 27,940,213, and the correct number of Tranche 2 shares is 5,393,120, each having a par value of NOK 0.15, with a subscription price of NOK 1.65 per share in the private placement. Consequently, following the issuance of Tranche 1 shares, the Company's share capital is increased with NOK 4,191,031.95 from NOK 42,018,983.25 to NOK 46,210,015.20, and the Company will have 308,066,768 shares issued

INVNT™ ANNOUNCED AS SPONSOR AND CO-PRODUCER OF DISCOVERY STAGE AT SXSW SYDNEY® 202420.5.2024 23:00:00 CEST | Press release

Also named as an endorsed Creative Experiential Partner for the 2024 event Sydney, May 20, 2024 (GLOBE NEWSWIRE) -- INVNT™, the Experiential Disrupter Agency, has today been announced as the sponsor and co-producer of the SXSW Sydney 2024 Discovery Stage after a successful collaboration at last year’s inaugural event. For the second consecutive year, INVNT will bring its world-class expertise in production and innovative brand storytelling and “Challenge Everything” ethos to SXSW Sydney, where it will continue its legacy of hosting, curating and presenting the Discovery Stage and activating across the event’s key pillars of Tech & Innovation, Music, Games and Screen. Featured within the SXSW Sydney Tech & Innovation Expo, the 2024 Discovery Stage will play host to inspiring innovation leaders who are redefining industry norms and will be a place to explore the latest developments in technology and meet startup founders who are poised to disrupt the status quo. As last year’s Discovery

Nokia Corporation: Repurchase of own shares on 20.05.202420.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 20 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 20.05.2024 Espoo, Finland – On 20 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL370,3933.56CEUX--BATE--AQEU--TQEX--Total370,3933.56 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM20.5.2024 20:15:00 CEST | Press release

Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammationData support the potential of Dupixent as the first new treatment approach in more than a decadeand first-ever targeted therapy for COPD Paris and Tarrytown, N.Y. May 20, 2024. Late-breaking data were presented from the NOTUS phase 3 study evaluating the investigational use of Dupixent® (dupilumab) as an add-on maintenance treatment in adults with uncontrolled COPD on maximal standard-of-care inhaled therapy (nearly all on triple therapy) and evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per μL). The NOTUS study confirmed the positive results demonstrated in the landmark phase 3 BOREAS s

HiddenA line styled icon from Orion Icon Library.Eye